Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference
-
Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery
-
Preclinical data demonstrates sustained efficacy and safety for six months or more following a single injection
VANCOUVER, Canada — May 6, 2025 — Optigo Biotherapeutics, a biotechnology company pioneering long-acting, bi-functional intravitreal biologics, today announced that it has been awarded the People’s Choice Award at Eyecelerator 2025 in Park City, Utah.
Concurrently, the company presented positive preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, supporting the potential of its proprietary anti-VEGF molecules to achieve dosing intervals of six months or longer in patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
The company’s proprietary biologics are fusion proteins that combine derisked therapeutics such as aflibercept with an albumin or hyaluronan anchoring domain. In VEGF challenge animal models, these bifunctional molecules demonstrate 2-3x longer half-life compared to aflibercept alone, were not proinflammatory, and were well tolerated with a favorable safety profile.
Optigo’s Eyecelerator presentation—“Developing Breakthrough Therapies to Restore Vision”—was delivered by Dr. Hemmati during the Retina TKI and Drug Delivery Showcase and was well-received by attendees for its bold, yet evidence-backed approach to solving one of the biggest challenges of chronic intravitreal therapy.
Optigo’s technology is well-positioned to capture a significant portion of the growing $14B anti-VEGF market by improving patient adherence and outcomes.
Optigo continues to actively engage with global pharmaceutical companies, biotech partners, and investors to accelerate development and bring this transformative technology to market.
Interested parties can view data and updates at:
​
About Optigo Biotherapeutics:
Optigo Biotherapeutics is a preclinical-stage biotechnology company developing a proprietary platform that anchors intravitreal biologics to endogenous proteins like albumin and hyaluronan, significantly prolonging half-life and therapeutic activity. The company’s lead program is a long-acting, bi-functional anti-VEGF therapy aimed at reducing injection burden in blinding retinal diseases such as nAMD, DME, and RVO. Optigo’s modular platform has broad applicability across retinal biologics requiring extended duration.
​
Media Contact:
RHMM PR
682.553.7283
